ArticleDiscover oncology2025
Analysis of immune status and prognostic model incorporating lactate metabolism and immune-related genes in clear cell renal cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Investigation of Endogenous Renal CEST Contrast and the Influence of Respiratory Motion on a Clinical 3 Tesla MRI: An In Vivo and In Vitro Study.Magnetic resonance in medicine · 2026Article
- The new insights of lactate in various kidney diseases.Expert reviews in molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is the most prevalent and highly aggressive subtype of kidney cancer. Despite the progress in research, the roles of lactate metabolism and immune-related genes (LMRGs) in its prognosis and immune microenvironment remain unclear. Until now, no studies have explored the potential impact of LMRGs on the prognosis of ccRCC and their relationship with the tumor immune microenvironment.
methodsTranscriptomic analysis was carried out using the TCGA and GEO databases. Non-negative matrix factorization (NMF) was used to subtype ccRCC samples. The Cox proportional hazards regression model and the LASSO algorithm were combined to screen the core genes related to prognosis. The Kaplan-Meier survival analysis was used to assess the relationship between these genes and patient survival. The CIBERSORT and ESTIMATE algorithms were used to analyze the level of immune infiltration.
resultsUsing NMF analysis, ccRCC samples were classified into two subtypes. Kaplan-Meier survival analysis revealed that patients in Cluster 2 exhibited a better prognosis than those in Cluster 1. LASSO regression analysis identified five key genes-STAT2, PDGFRL, APLNR, PRKCQ, and THRB-which were subsequently used to construct a prognostic model. The survival rate in the high-risk group was significantly lower than that in the low-risk group. Immune microenvironment analysis demonstrated that the high-risk group exhibited higher immune cell infiltration, while the low-risk group was enriched for metabolism-related pathways. Tumor mutation burden (TMB) analysis indicated that TMB synergized with the risk score. Finally, the prognostic value of these key genes was validated using the K-M database.
conclusionLactate metabolism and immune-related genes are of great significance in the prognostic evaluation of ccRCC. The core genes screened based on these mechanisms have the potential value as biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.